title: Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma.
abstract: OBJECTIVE
  To compare 24 h intraocular pressure (IOP) control of morning and evening administered bimatoprost/timolol fixed combination (BTFC) and evening administered bimatoprost in exfoliative glaucoma (XFG).
  
  
  METHODS
  One eye of 60 XFG patients was included in this prospective, observer-masked, crossover comparison. Following wash-out, all patients received bimatoprost monotherapy for 6 weeks. They were then randomised to morning, or evening, administered BTFC for 3 months and then switched to the opposite therapy.
  
  
  RESULTS
  At baseline, mean 24 h pressure was 29.0 mm Hg. Bimatoprost reduced the mean IOP by 8.1 mm Hg (27.8%, p<0.001). The evening administration of BTFC reduced 24 h IOP to a statistically lower level than morning administration (10.2 mm Hg (35.3%) vs 9.8 mm Hg (33.8%); p=0.005). Both dosing regimens reduced IOP significantly more than bimatoprost (p < or = 0.006, for all time points). A 24 h IOP reduction > or = 30% was seen in 43 patients (72%) with evening BTFC compared with 39 patients (65%) with morning BTFC (p=0.344) and only 24 patients (40%) with bimatoprost monotherapy (p<0.001 vs both BTFC regimens).
  
  
  CONCLUSIONS
  Both BTFC dosing regimens significantly reduce 24 h IOP in XFG compared with bimatoprost monotherapy. The evening dosing gives rise to statistically better 24 h IOP control and could be considered in these patients.
authors.affiliation: Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital, 1 Kyriakidi Str, Thessaloniki 546 36, Greece. konstas@med.auth.gr
authors.forename: Anastasios G P
authors.initials: AG
authors.lastname: Konstas
authors.forename: Gábor
authors.initials: G
authors.lastname: Holló
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Mikropoulos
authors.forename: Sevasti
authors.initials: S
authors.lastname: Tsironi
authors.forename: Anna-Bettina
authors.initials: AB
authors.lastname: Haidich
authors.forename: Theodoros
authors.initials: T
authors.lastname: Embeslidis
authors.forename: Irene
authors.initials: I
authors.lastname: Georgiadou
authors.forename: Murat
authors.initials: M
authors.lastname: Irkec
authors.forename: Shlomo
authors.initials: S
authors.lastname: Melamed
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000008:administration & dosage* / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069580:Bimatoprost; D002940:Circadian Rhythm / Q000502:physiology; D003008:Cloprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004338:Drug Combinations; D017889:Exfoliation Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D013999:Timolol / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D004338:Drug Combinations; D003008:Cloprostenol; D013999:Timolol; D000069580:Bimatoprost